Halda has advanced the next wave of induced proximity drugs into the clinic, expanding the case for bifunctional molecules that act by sticking two proteins together. Whereas the first act for these ...
NEW YORK & NEW HAVEN, Conn.--(BUSINESS WIRE)--VantAI, the leader in generative AI for proximity drug discovery, and Halda Therapeutics, the pioneer of RIPTAC (Regulated Induced Proximity Targeting ...
Proceeds will fund advancement of ARON degrader, FX-111, to proof of concept and preclinical development of ARON RIPTAC program- Veteran ...
US-based biotechnology company Halda Therapeutics has secured $126m in a Series B extension financing round to progress some of its cancer therapies into clinical trials. The company's Regulated ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC TM (Regulated Induced Proximity TArgeting Chimeras) ...
Two decades after Craig M. Crews, PhD, successfully developed cancer therapies based on degrading unwanted or harmful proteins in cells, a six-year-old startup founded by the Yale University professor ...
Halda Therapeutics, based in New Haven, Connecticut, is developing a new class of therapies called regulated induced proximity targeting chimeras (RIPTACs) to treat cancer. The company, with $76 ...
In a presentation at the American Chemical Society meeting, Halda Therapeutics Inc. described its androgen receptor (AR)-targeting RIPTAC (regulated induced proximity targeting chimera) therapeutics ...
Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC(TM) (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced the ...
Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash. This move brings Halda’s Regulated Induced Proximity Targeting ...
Collaboration integrates VantAI’s frontier AI and structural proteomics discovery platform with Halda’s novel and clinically validated RIPTAC™ modality to unlock novel, cell-selective approaches in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results